The cognitive effects of cholinesterase inhibitor treatment in every-day practice

Current Medical Research and Opinion

Volumn 21, Issue 6, 2005, Pages 871-875

  Kapaki, Elisabeth ^a   Paraskevas, G P ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Donepezil; Galantamine; Mixed dementia; Rivastigmine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE; TACRINE;

ADULT; AGED; ALZHEIMER DISEASE; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITION; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; REVIEW; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION; FEMALE; GREECE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 21244448825     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X46359     Document Type: Review

References (21)

1. Moghul S, Wilkinson D. Use of acetylcholinesterase inhibitors in Alzheimer's disease. Expert Rev Neurotherapeutics 2001;1:61-9
2. Farlow M, Anand R, Messina J, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000;44:236-41
3. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD. A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261-8
4. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-95
5. Waldemar G, Dubois B, Emre M, et al. Diagnosis and management of Alzheimer's disease and other disorders associated with dementia. The role of neurologists in Europe. Eur J Neurol 2000;7:133-44
6. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154-66
7. NICE (National Institute of Clinical Excellence). Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease [online]. Available from http:// www.nice.org.uk [accessed 2001]
8. Kumar V, Anand R, Messina J, et al. An efficacy and safety analysis of Exelon® in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol 2000;7:159-69
9. Moretti R, Torre P, Antonello RM, Cazzato G. Rivastigmine in subcortical vascular dementia: an open 22-month study. J Neurol Sci 2002;203-204:141-6
10. Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;359:1283-90
11. Black S, Román G, Geldmacher DS, et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003;34:2323-32
12. McKhann G, Drachman D, Holstein M, et al. Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44
13. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-60
14. Folstein M, Folstein S, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98
15. McLendon BM, Doraiswamy PM. Defining meaningful change in Alzheimer's disease trials: the donepezil experience. J Geriatr Psychiatry Neurol 1999;12:39-48
16. Burback D, Molnar FJ, St John P, Man-Son-Hing M. Key methodological features of randomized controlled trials of Alzheimer's disease therapy: minimal clinically important difference, sample size and trial design. Dementia Geriatr Cogn Disord 1999; 10:534-40
17. Giacobini E. Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer's disease. Alzheimer Dis Assoc Disord 2000; 14:S3-S10
18. Lanctôt KL, Hermann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. Can Med Assoc J 2003;169:557-64
19. Giacobini E. Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy. In: Cholinesterases and cholinesterase inhibitors. London: Martin Dunitz Ltd; 2000. p. 181-226
20. Arias E, Alés E, Gabilan NH, et al. Galantamine prevents apoptosis induced by β-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology 2004;46:103-14
21. Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease. Arch Neurol 2001;58:427-33